BMY Earnings Prediction
The chart below shows how BMY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BMY sees a -0.17% change in stock price 10 days leading up to the earnings, and a +0.56% change 10 days following the report. On the earnings day itself, the stock moves by +0.11%. This data can give you a slight idea of what to expect for the next quarter's release.
BMY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
11.89B
8.44%
-2.53%
Gross Margin
55.75%
-1.71%
-0.18%
Operating Margin
23.25%
-6.10%
-7.07%
Net Margin
10.22%
-42.06%
-25.94%
EPS
0.60
-35.48%
-27.71%
No Data Available
BMY Earnings Analysis
Bristol-Myers Squibb Co. Corporation (BMY.N) Earnings Conference Call
Positive
Portfolio Revenue Increase: Growth portfolio revenues increased 20% in Q3 at constant currency, now accounting for approximately half of total revenues.
Reblozyl Sales Surge: Sales of Reblozyl grew 81% in the third quarter, driven by strong demand in both U.S. and international markets.
Camzyos Sales Surge: Sales of Camzyos more than doubled, driven by strong U.S. demand for new patient starts and an increasing number of patients on commercial drug.
Breyanzi Sales Surge: Sales of Breyanzi more than doubled versus prior year, driven by demand in new indications and improved manufacturing capacity and reliability.
Cash Reserves for Investments: The company ended the quarter with approximately $8.4 billion in cash, cash equivalents, and marketable debt securities on hand, supporting strategic investments.
Negative
Legacy Portfolio Sales Decline: 1. Declining Sales from Legacy Portfolio: The legacy portfolio's sales were negatively impacted by the loss of exclusivity for Sprycel in the U.S. and Pomalyst in Europe, contributing to lower overall revenue growth despite gains in other areas.
Inventory Reversal Effects: 2. Inventory Reversal Impact: The third quarter sales growth was tempered by a reversal of approximately $150 million in inventory build from the second quarter, affecting brands like Opdivo and Opdualag.
Rising Operating Expenses: 3. Increased Operating Expenses: Operating expenses, excluding in-process R&D, are expected to increase by approximately 4% to 5% for the year, driven by higher spending to support the product portfolio and pipeline.
Increased Tax Burden: 4. Higher Effective Tax Rate: The effective tax rate increased from 11.6% in the prior year to 18.5%, influenced by a one-time adjustment due to newly issued IRS guidance, impacting overall profitability.
Legacy Brand Generic Erosion: 5. Generic Erosion in Legacy Brands: The company anticipates further generic erosion in the fourth quarter for legacy brands like Sprycel and Pomalyst, which could negatively affect revenue projections.
BMY FAQs
How does BMY typically perform around its earnings report dates?
Is Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BMY Earning Call Sentiment
Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BMY.N
1.63%Positive
The earnings call summary indicates strong financial performance with increased sales, debt reduction, and raised EPS guidance. The Q&A section reveals confidence in future growth and positive sentiment from analysts. Despite a decline in gross margin, the overall outlook is optimistic with a focus on new product launches and strategic initiatives. The raised revenue and EPS guidance further support a positive sentiment. Considering the potential market impact of these developments, a positive stock price movement is anticipated over the next two weeks.